<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00239018</url>
  </required_header>
  <id_info>
    <org_study_id>CERL080A2405FR01E1</org_study_id>
    <nct_id>NCT00239018</nct_id>
  </id_info>
  <brief_title>Extension Study on the Efficacy and Safety of Enteric-coated Mycophenolate Sodium Administered in de Novo Kidney Transplant Patients</brief_title>
  <official_title>A Prospective, Open-label, Multicenter, Follow-up Study on the Efficacy and Safety of Enteric-coated Mycophenolate Sodium Administered in de Novo Kidney Transplant Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The objective of this extension study is to allow patients being treated with enteric-coated
      mycophenolate sodium (core study CERL080A2405FR01) to continue on the same treatment and to
      assess the long-term safety of EC-MPS
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">July 2005</completion_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess glomerular filtration rate at month 3 post transplantation</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal function of patients requiring post transplantation dialysis, experiencing slow graft function (defined as S. Creat level&gt;264 μmol/l at D5) or with immediate graft function.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of patients requiring post transplantation dialysis, experience slow graft function (defined as S. Creat level&gt;264 μmol/l at D5 or with immediate graft function.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of biopsy proven acute rejection, any treated acute rejection, and any treated acute rejection requiring antibody therapy, recurrent acute rejection and the severity of acute rejection episodes within 6 and 12 months</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of graft and patient survival within 6 and 12 months</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability based on adverse event (AE) reporting.</measure>
  </secondary_outcome>
  <enrollment type="Actual">144</enrollment>
  <condition>De Novo Kidney Transplantation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enteric-Coated Mycophenolate Sodium (EC-MPS)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion / Exclusion Criteria

        - All patients who completed study CERL080A2405-FR01 and who are willing to continue
        treatment with Enteric-Coated Mycophenolate Sodium.

        Other protocol-defined inclusion / exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Study Director</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2005</study_first_submitted>
  <study_first_submitted_qc>October 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2005</study_first_posted>
  <last_update_submitted>January 28, 2011</last_update_submitted>
  <last_update_submitted_qc>January 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2011</last_update_posted>
  <responsible_party>
    <name_title>Novartis</name_title>
    <organization>Novartis</organization>
  </responsible_party>
  <keyword>Enteric-Coated Mycophenolate Sodium (EC-MPS), de novo, kidney transplantation, long-term safety.</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

